Five Biotech Stocks to Pick Up on the Cheap


With second-quarter earnings coming up, Bernstein's Aaron Gal takes a look at what to expect from some biotech firms. He writes that the sector remains unloved in the overall market, with investors wary of buying into biotech ahead of what they see as a coming restructuring of the industry, which will catch up to drug companies that have been "over earning."



from Biotech News